Aptose Biosciences Reports $7.6 Million Net Loss in Q1 2026, Faces Financial Challenges

Aptose Biosciences Inc. reported a net loss of $7.6 million for the first quarter of 2026, an increase from the $5.5 million loss recorded in the same period of 2025. The company's total operating expenses rose to $7.2 million, up from $5.5 million year-over-year, primarily driven by increased research and development costs associated with its lead program, tuspetinib. Research and development expenses alone reached $3.6 million, compared to $2.4 million in the prior year, reflecting heightened activity in the ongoing TUSCANY clinical trial for acute myeloid leukemia (AML). General and administrative expenses also increased to $3.6 million from $3.1 million, largely due to higher professional fees and regulatory costs.

As of March 31, 2026, Aptose's total assets amounted to $10.7 million, a slight increase from $10.0 million at the end of 2025. The company reported current liabilities of $11.2 million, leading to a working capital deficit of $5.1 million. The accumulated deficit stood at $574.1 million, indicating ongoing financial challenges. The company’s cash and restricted cash totaled $4.1 million, which is critical as it continues to rely on external financing to support its operations. The company has entered into a Second Amended Facility Agreement with Hanmi Pharmaceutical Co. Ltd., which provides up to $11.1 million in funding for the continued development of tuspetinib.

Strategically, Aptose is advancing its clinical pipeline, particularly focusing on tuspetinib, which is being developed as a treatment for newly diagnosed AML patients. The TUSCANY trial is exploring the efficacy of tuspetinib in combination with standard therapies, and preliminary results have shown promising safety and efficacy profiles. However, the company has also announced the cessation of its Luxeptinib program, returning all associated rights to CrystalGenomics, as part of its strategic realignment.

Looking ahead, Aptose faces significant challenges in securing additional financing to sustain its operations and clinical programs. The company has acknowledged the need for further capital and is exploring various options, including debt financing and potential collaborations. The ongoing uncertainty regarding its ability to raise funds, coupled with the recent delisting from Nasdaq, raises substantial doubt about its ability to continue as a going concern. The company is expected to provide updates on its clinical trials and financial status in the coming months, particularly as it approaches the anticipated closing of the Arrangement Agreement with Hanmi, which could provide additional liquidity.